A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
The primary objective of the study is to determine whether quizartinib monotherapy prolongs
overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine
kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have
relapsed within 6 months, after first-line AML therapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society